BMS 986205

Drug Profile

BMS 986205

Alternative Names: BMS986205; ONO-7701

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Jul 2017 Phase-I clinical trials in Cancer (In volunteers) in USA (PO) (NCT03247283)
  • 01 Jul 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Japan (unspecified route) (NCT03192943)
  • 28 Jun 2017 Bristol-Myers Squibb plans a phase I trial for Cancer (Second-line therapy or greater, Combination therapy, Late-stage disease, Inoperable/Unresectable) in Japan (NCT03192943)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top